NIKKEI 225
38,236.68 +182.55 (+0.48%) HANG SENG
18,230.19 -246.82 (-1.34%) CRUDE OIL
77.72 -0.19 (-0.24%) GOLD FUTURES
2,366.00 -0.50 (-0.02%) DOW
38,111.48 -330.06 (-0.86%) Bitcoin GBP
53,650.69 +528.44 (+0.99%)
Gilead Sciences Inc (GIS.BE)
- Business Wire
Gilead Provides Update on Phase 3 TROPiCS-04 Study
FOSTER CITY, Calif., May 30, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) today announced topline results from the confirmatory Phase 3 TROPiCS-04 study in locally advanced or metastatic urothelial cancer (mUC). The TROPiCS-04 study evaluated Trodelvy® (sacituzumab govitecan-hziy; SG) vs. single-agent chemotherapy (treatment of physicians’ choice, TPC) in patients with mUC who have previously received platinum-containing chemotherapy and anti-PD-(L)1 therapy.
- Business Wire
Gilead to Present Latest Research Across Key Liver Disease Indications at the European Association for the Study of the Liver Congress 2024
FOSTER CITY, Calif., May 22, 2024--Gilead Sciences, Inc. (Nasdaq:GILD) today announced new research to be presented at the European Association for the Study of the Liver (EASL) Congress, June 5-8, 2024 in Milan, Italy. Key findings from more than 25 abstracts will include:
- Zacks
Here is What to Know Beyond Why Gilead Sciences, Inc. (GILD) is a Trending Stock
Recently, Zacks.com users have been paying close attention to Gilead (GILD). This makes it worthwhile to examine what the stock has in store.
